Research Peptides Database

A small molecule NNMT inhibitor that promotes fat cell metabolism and may support weight loss without affecting the central nervous system.

An FDA-approved synthetic analog of parathyroid hormone-related protein (PTHrP) that promotes bone formation and reduces fracture risk in postmenopausal osteoporosis.

A chimeric proapoptotic peptide that selectively targets the vasculature of white adipose tissue, inducing fat cell death through blood supply disruption.

A modified fragment of human growth hormone designed to stimulate fat metabolism without the growth-promoting effects of full HGH.

An 11-amino acid erythropoietin-derived peptide that activates the innate repair receptor for tissue protection without hematopoietic effects.

A topical cosmetic peptide marketed as 'Botox in a jar' that reduces wrinkle appearance by inhibiting muscle contraction at the neuromuscular junction.

A gastric pentadecapeptide with remarkable tissue-protective and regenerative properties across multiple organ systems.

A long-acting amylin analog that suppresses appetite and enhances satiety—being developed by Novo Nordisk as a complement to GLP-1 drugs for superior weight loss.

A neuropeptide preparation derived from pig brain that mimics neurotrophic factors—used clinically in many countries for stroke, dementia, and traumatic brain injury.

A synthetic GHRH analog with enhanced stability and prolonged GH-releasing activity, available in both standard and DAC-conjugated forms.

A neuropeptide with potent anti-inflammatory and immunomodulatory properties, closely related to somatostatin but with distinct receptors and therapeutic potential.

An extremely potent cognitive-enhancing compound derived from angiotensin IV, studied for memory enhancement and potential neurodegenerative disease applications.

A naturally occurring neuropeptide that promotes deep delta-wave sleep, stress resilience, and may help normalize disrupted sleep patterns.

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and cardiovascular risk reduction, administered once weekly.

A tetrapeptide that activates telomerase, the enzyme responsible for maintaining telomere length, potentially addressing one of the fundamental mechanisms of cellular aging.

The first GLP-1 receptor agonist approved for diabetes, derived from Gila monster venom, available in twice-daily and once-weekly formulations.

A myostatin inhibitor and activin-binding protein that promotes muscle growth by blocking the body's natural limiters on muscle development.

A naturally occurring copper peptide with powerful skin regeneration, wound healing, and anti-aging properties backed by decades of research.

The primary hunger hormone that stimulates appetite, GH release, and gastric motility—the natural ligand for the GHS receptor targeted by GHRPs.

A potent growth hormone secretagogue that balances strong GH release with more moderate appetite stimulation than GHRP-6, making it a middle-ground option.

A potent growth hormone secretagogue known for robust GH release and significant appetite stimulation—the original GH-releasing peptide that started the secretagogue era.

The body's master antioxidant — a tripeptide critical for detoxification, oxidative stress defense, immune function, and cellular health.

The natural gonadotropin-releasing hormone used to stimulate LH and FSH production, commonly used in fertility treatment and post-cycle therapy research.

A potent synthetic growth hormone releasing hexapeptide with unique cardioprotective properties and the strongest GH release among GHRP family peptides.

The C-terminal fragment of human growth hormone responsible for fat metabolism, studied for its lipolytic activity without the growth-promoting effects of full-length HGH.

A mitochondrial-derived peptide with cytoprotective and neuroprotective properties, showing promise in aging, Alzheimer's research, and metabolic health.

A truncated, highly potent variant of IGF-1 that bypasses binding proteins for enhanced bioavailability and tissue-specific anabolic effects.

A potent, extended-acting analog of IGF-1 with enhanced tissue availability and reduced binding protein affinity for research applications.

A highly selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol, prolactin, or appetite hormones.

A neuropeptide that serves as the master regulator of the reproductive axis, controlling GnRH release and fertility in both sexes.

A master regulator of the reproductive hormone system that triggers natural LH and testosterone release, with potential applications in fertility, hormone optimization, and PCT.

A potent anti-inflammatory tripeptide derived from alpha-MSH with remarkable effects on inflammatory bowel conditions and immune modulation.

A naturally-occurring dipeptide with potent anti-glycation, antioxidant, and anti-aging properties found in high concentrations in muscle and brain tissue.

A long-acting somatostatin analog for acromegaly and neuroendocrine tumors—with the convenience of self-injectable depot formulation.

An FDA-approved 14-amino acid peptide that activates guanylate cyclase-C receptors to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, with extensive clinical trial evidence supporting its metabolic benefits.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes with unique pharmacokinetics favoring postprandial glucose control.

A human host defense peptide with broad-spectrum antimicrobial activity and powerful immunomodulatory properties for wound healing and infection control.

A collagen-boosting signal peptide widely used in anti-aging skincare to reduce wrinkles and improve skin firmness.

An FDA-approved synthetic melanocortin peptide analog that stimulates melanogenesis for photoprotection, with clinical applications in erythropoietic protoporphyria and vitiligo research.

A synthetic melanocortin peptide that stimulates melanin production, developed for photoprotection and approved for treating erythropoietic protoporphyria (EPP).

A synthetic peptide that stimulates melanin production for skin tanning while also producing notable effects on libido and appetite suppression.

A synthetic melanocortin peptide analog that stimulates melanin production for skin pigmentation and activates sexual arousal pathways.

A splice variant of IGF-1 released in response to muscle damage, promoting satellite cell activation and muscle repair.

An orally-active growth hormone secretagogue that mimics ghrelin signaling to increase GH and IGF-1 levels without injections.

A modified growth hormone-releasing hormone analog with enhanced stability, commonly paired with GHRPs for synergistic GH release.

A mitochondria-derived peptide with profound effects on metabolism, exercise capacity, and aging—a rising star in longevity research.

An enhanced variant of Selank with improved stability and bioavailability, offering anxiolytic and cognitive effects through GABA modulation.

An enhanced variant of Semax with improved stability and potency, offering cognitive enhancement and neuroprotective effects.

An 82-amino acid peptide derived from nucleobindin-2 that regulates appetite, metabolism, and energy homeostasis through hypothalamic signaling.

A 36-amino acid neuropeptide that serves as one of the most abundant signaling molecules in the brain, regulating appetite, stress response, anxiety, and circadian rhythms.

A synthetic somatostatin analog used to treat acromegaly, carcinoid tumors, and severe diarrhea—one of the most clinically important peptide drugs in endocrinology.

A neuropeptide critical for wakefulness, appetite regulation, and energy homeostasis with therapeutic implications for narcolepsy and metabolic disorders.

A nine-amino acid neuropeptide hormone involved in social bonding, trust, anxiety reduction, and reproductive functions.

A synthetic 21-amino acid peptide derived from Ciliary Neurotrophic Factor (CNTF) that promotes neurogenesis and cognitive enhancement.

A 38-amino acid neuropeptide with potent neuroprotective, anti-inflammatory, and regenerative properties across multiple organ systems.

A pegylated variant of IGF-1 splice variant with extended half-life, studied for localized muscle repair and hypertrophy signaling.

A GLP-1/glucagon dual agonist designed for better body composition—promoting fat loss while preserving muscle mass during weight loss.

A gut-derived satiety hormone that reduces appetite and regulates energy balance, with significant research implications for obesity treatment.

A synthetic bioregulatory tripeptide that targets pineal gland and central nervous system function, with neuroprotective and geroprotective properties.

An FDA-approved synthetic amylin analog that complements insulin therapy by slowing gastric emptying, reducing glucagon secretion, and enhancing satiety in diabetes management.

An FDA-approved melanocortin receptor agonist that acts centrally in the brain to promote sexual arousal and desire.

A cell-penetrating peptide targeting the Wnt/β-catenin pathway to activate hair follicle stem cells and promote hair regrowth.

A groundbreaking triple receptor agonist achieving unprecedented 24.2% weight loss in clinical trials, representing the next evolution in obesity pharmacotherapy.

A synthetic anxiolytic peptide derived from tuftsin, developed in Russia for anxiety reduction, cognitive enhancement, and immunomodulation.

A GLP-1 receptor agonist that mimics natural gut hormones to reduce appetite, slow digestion, and support significant weight loss results.

A synthetic heptapeptide nootropic derived from ACTH with neuroprotective, cognitive-enhancing, and neurorestorative properties.

A synthetic 29-amino acid peptide analog of growth hormone-releasing hormone (GHRH) that stimulates natural GH production from the pituitary gland.

An FDA-approved MC4R agonist peptide for treating obesity caused by rare genetic disorders affecting the leptin-melanocortin pathway.

An 8-amino acid peptide that mimics the N-terminus of SNAP-25 to reduce muscle contractions and soften expression lines without injections.

A mitochondria-targeting peptide that protects cells from oxidative damage and restores energy production—in clinical trials for heart failure and mitochondrial diseases.

A dual GLP-1 and glucagon receptor agonist showing significant weight loss and liver fat reduction in clinical trials, positioned as a next-generation obesity and MASH therapeutic.

A synthetic peptide fragment promoting tissue repair, reduced inflammation, and accelerated recovery from muscle, tendon, and ligament injuries.

An FDA-approved parathyroid hormone analog used to treat osteoporosis by stimulating new bone formation rather than just preventing bone loss.

An FDA-approved growth hormone-releasing hormone analog that reduces visceral fat accumulation and stimulates natural GH production.

A thymic polypeptide bioregulator with immunomodulatory and geroprotective properties, developed from decades of Russian peptide bioregulation research.

A synthetic pentapeptide derived from thymopoietin that modulates T-cell function and enhances immune system regulation.

Thymosin Alpha 1 is a synthetic 28–amino acid peptide studied for its immunomodulatory effects, supporting host defense, tissue recovery, and immune balance in diverse experimental models.

A 43-amino acid protein that orchestrates tissue repair, cell migration, and wound healing—the full molecule behind TB-500's regenerative reputation.

A zinc-dependent thymic nonapeptide essential for T-cell maturation, immune regulation, and emerging anti-aging research.

A dual-action incretin that has achieved unprecedented weight loss results in clinical trials, now FDA-approved as Mounjaro and Zepbound.

A 28-amino acid neuropeptide with potent anti-inflammatory, immunomodulatory, and neuroprotective properties being researched for autoimmune conditions and gut disorders.

An FDA-approved modified C-type natriuretic peptide (CNP) analog that promotes bone growth by counteracting FGFR3 signaling in children with achondroplasia.